Provide long read sequencing kits to the laboratory of neurogenetics (LNG) for neurodegenerative disease research.
Ended Purchase Order Awarded Last action
- Contract number
- 75N95020P00606
- Awardee
-
Oxford Nanopore Technologies, Inc. UEI FM6MMNBM2TQ5 Part of Oxford Nanopore Technologies PLC
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,959,768
Award facts
- Opportunity
-
- 75N95020Q00114 Solicitation number
- Contract value 100% obligated
- $2,959,768.21 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02139, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$39,439 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,999,207 |
About this award
The National Institute on Drug Abuse awarded a $2.96 million firm fixed-price purchase order to Oxford Nanopore Technologies Inc. on September 14, 2020, for the delivery of long-read sequencing kits to support the Laboratory of Neurogenetics' neurodegenerative disease research initiatives. The contract, which was completed on November 13, 2020, involved no set-aside designation and specified performance at Oxford Nanopore's Cambridge, Massachusetts location. Oxford Nanopore Technologies Inc., a foreign-owned biotechnology company specializing in nanopore-based electronic systems for DNA and RNA analysis, has established itself as a key supplier of advanced genomic sequencing technologies to multiple federal agencies, including the National Institutes of Health, Centers for Disease Control and Prevention, and the Department of Defense.
This purchase order reflects the government's continued investment in cutting-edge genomic sequencing capabilities for neurological research. The contract also served an administrative function to de-obligate unexpended and expiring fiscal year 2020 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2025 closing of the period of availability for those funds. Oxford Nanopore's sequencing platforms, including the MinION and PromethION systems, provide researchers with real-time, long-read DNA and RNA analysis capabilities essential for studying complex neurodegenerative conditions. The company's extensive portfolio of federal contracts demonstrates its capacity to deliver sophisticated genomic sequencing products and services across diverse scientific applications and research domains.
Quick answers
Who was awarded contract 75N95020P00606?
75N95020P00606 was awarded to Oxford Nanopore Technologies, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 14, 2020.
How much is contract 75N95020P00606 worth?
The government has obligated $2,959,768 on 75N95020P00606.
Was contract 75N95020P00606 competed?
The extent of competition for 75N95020P00606 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award